

Coronavirus and Other Respiratory Viruses Surveillance and Prevention Branch (CVGHC)

(1) Conducts surveillance and related activities to monitor patterns of respiratory virus infection and disease incidence and assess impact of interventions; (2) provides technical expertise and support to state and local health departments for surveillance and related activities; (3) provides expertise and support on data analysis and visualization of respiratory virus surveillance data for internal and external use; (4) performs applied modeling analyses to characterize disease burden and impact of interventions; (5) conducts vaccine effectiveness evaluations for coronaviruses and other respiratory viruses to support the development and evaluation of immunization practices and policies; (6) analyzes and synthesizes available data and develops science-based statements for potential respiratory viral vaccines to support the development and evaluation of immunization practices and policies related to coronaviruses and other respiratory virus vaccines by ACIP and other groups; (7) Coordinates quantitative science and data management planning, policy development, and project monitoring and evaluation; (8) designs, develops and conducts statistical, economic, cost, resource allocation, geospatial and other analyses and models; (9) develops data management methodologies and strategies for division activities and programs; and (10) collaborates with scientists, program experts, and senior public health officials throughout the division to implement strategies, models, and methodologies in support of enteric, and related viral disease research, surveillance, and prevention programs.

Coronavirus and Other Respiratory Viruses Epidemiology Branch (CVGHD)

(1) Characterizes the spectrum of disease and sequelae from respiratory virus infections, including, but not limited to multisystem inflammatory syndrome and post-COVID conditions, the burden and incidence of sequelae, and risk factors for sequelae; (2) characterizes transmission dynamics and risk factors for coronavirus and other respiratory virus infections; (3) characterizes acute and long-term immunity to understand correlates of protection; (4) conducts and supports field epidemiologic studies to characterize unusual disease clusters and unexpected disease manifestations or trends of viral respiratory diseases;

(5) provides consultation and technical assistance to state and local health departments and others in the investigation, management, mitigation and control of viral respiratory disease clusters and outbreaks; (6) evaluates the implementation, effectiveness and impact of community-level mitigation measures; (7) develops and updates public health guidance on community-based non-pharmaceutical interventions for the prevention and control of respiratory viruses, such as masking, screening, quarantine, and isolation; and (8) provides consultation and technical support on clinical management and secondary prevention for respiratory viral diseases.

Global Coronavirus and Other Respiratory Viruses Branch (CVGHE)

(1) Implements global respiratory virus surveillance including supporting enhanced epidemiologic and laboratory capacity and data analyses to improve understanding of the epidemiological characteristics, trends, and emergence of respiratory pathogens; (2) builds capacity for global surveillance and epidemic intelligence to detect and respond to respiratory events including those of pandemic potential; (3) assists global partners in pandemic preparedness activities; (4) provides support and/or participates in investigations of international respiratory outbreaks including implementing appropriate control measures; (5) conducts research studies with global partners, division, and agency stakeholders to better understand burden of disease, impact of prevention programs, and molecular epidemiology of respiratory viruses; (6) provides technical assistance to global partners to conduct or support comprehensive antigenic, phenotypic, genotypic, structural, and evolutionary characterization of SARS-CoV-2 and respiratory viruses; and (7) provides expertise to global partners in the development of evidence-based surveillance standards and methods.

Delegations of Authority

All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, provided they are consistent with this reorganization. (Authority: 44 U.S.C. 3101)

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2023-02930 Filed 2-10-23; 8:45 am]

BILLING CODE 4160-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 117-286. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected.

Date: May 11-12, 2023.

Time: 10 a.m.-5 p.m. (EDT).

Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.

Agenda: To review and evaluate grant applications.

For Further Information Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: GAnderson@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-02970 Filed 2-10-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 117-286. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—PS23-004, Long-Acting Injectables for the Treatment of HIV in Non-Clinic Community-Based Settings and PS23-006, Identifying and Addressing Historical and Structural Drivers of Medical Mistrust among Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex with Men (HLSM) for HIV Prevention.

Date: April 26-27, 2023.

Time: 10 a.m.-5 p.m. (EDT).

Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.

Agenda: To review and evaluate grant applications.

For Further Information Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: GAnderson@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease

Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-02972 Filed 2-10-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Healthcare Infection Control Practices Advisory Committee; Notice of Charter Renewal

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of charter renewal.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS) announces the renewal of the charter of the Healthcare Infection Control Practices Advisory Committee (HICPAC).

FOR FURTHER INFORMATION CONTACT: Sydnee Byrd, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16-3, Atlanta, Georgia 30329-4027; Telephone: (404) 718-8039; Email: HICPAC@cdc.gov.

SUPPLEMENTARY INFORMATION: CDC is providing notice under 5 U.S.C. 1001-1014. This charter has been renewed for a two-year period through January 19, 2025.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-02969 Filed 2-10-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 117-286. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—SIP23-001, Effective Community Conversations for Influenza and COVID-19 Vaccine Uptake.

Date: May 2, 2023.

Time: 11 a.m.-3 p.m., EDT.

Place: Teleconference.

Agenda: To review and evaluate grant applications.

For Further Information Contact: Catherine Barrett, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S107-3, Atlanta, Georgia 30341-3717; Telephone: (770) 718-7664; Email: CBarrett@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-02973 Filed 2-10-23; 8:45 am]

BILLING CODE 4163-18-P